日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Feed Modification for Improved Energy and Protein Provision for Infants and Young Children in the Pediatric Critical Care Setting: A Scoping Review

改善儿科重症监护环境下婴幼儿能量和蛋白质供应的喂养方案调整：一项范围界定综述

期刊:Nutrition Reviews
影响因子:4.9
doi:10.1093/nutrit/nuaf154
Winderlich, Jacinta; Little, Bridget S; Bendall, Cassandra; Anderson, Alice; Oberender, Felix; Udy, Andrew A; Ridley, Emma J
发表日期：2025
文献求助 收藏

Meal plan inclusions and exclusions in the inpatient, outpatient and community setting for adolescent and adult eating disorder care: a scoping review

青少年和成人饮食障碍治疗中住院、门诊和社区环境下膳食计划的包含和排除情况：一项范围界定综述

期刊:Journal of Eating Disorders
影响因子:4.5
doi:10.1186/s40337-025-01410-y
Bendall, Cassandra; Winderlich, Jacinta; Anderson, Alice; Caughey, Michelle; Hoy, Jamie; Coleman, Jacinta; Bennett, Christie Jane
发表日期：2025
文献求助 收藏

Consumer and community involvement in paediatric intensive care research across Australia and New Zealand: a protocol for a mixed-methods environmental scan

澳大利亚和新西兰儿科重症监护研究中消费者和社区参与：混合方法环境扫描方案

期刊:
影响因子:
doi:10.1186/s40900-025-00734-y
Serratore, Alyssa; O'Neill, Jenny; Jenkinson, Bec; Khan, Aisha; Butler, Ashleigh E; Masterson, Kate; Winderlich, Jacinta; Woodgate, Jemma; Raman, Sainath; Gibbons, Kristen S
发表日期：2025
文献求助 收藏

Establishing a paediatric critical care core quality measure set using a multistakeholder, consensus-driven process

利用多方利益相关者参与、共识驱动的流程，建立儿科重症监护核心质量指标集。

期刊:Critical Care and Resuscitation
影响因子:1.7
doi:10.1016/j.ccrj.2024.01.002
Schults, Jessica A; Charles, Karina R; Millar, Johnny; Rickard, Claire M; Chopra, Vineet; Lake, Anna; Gibbons, Kristen; Long, Debbie; Rahiman, Sarfaraz; Hutching, Katrina; Winderlich, Jacinta; Spotswood, Naomi E; Johansen, Amy; Secombe, Paul; Pizimolas, Georgina A; Tu, Quyen; Waak, Michaela; Allen, Meredith; McMullan, Brendan; Hall, Lisa
发表日期：2024
文献求助 收藏

RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma

RE-MIND2：基于真实世界数据，比较 tafasitamab 联合来那度胺与 polatuzumab vedotin/bendamustine/rituximab (pola-BR)、CAR-T 疗法以及来那度胺/rituximab (R2) 在复发/难治性弥漫性大 B 细胞淋巴瘤患者中的疗效

期刊:Annals of Hematology
影响因子:2.4
doi:10.1007/s00277-023-05196-4
Nowakowski, Grzegorz S; Yoon, Dok Hyun; Mondello, Patrizia; Joffe, Erel; Peters, Anthea; Fleury, Isabelle; Greil, Richard; Ku, Matthew; Marks, Reinhard; Kim, Kibum; Zinzani, Pier Luigi; Trotman, Judith; Sabatelli, Lorenzo; Waltl, Eva E; Winderlich, Mark; Sporchia, Andrea; Kurukulasuriya, Nuwan C; Cordoba, Raul; Hess, Georg; Salles, Gilles
细胞生物学
淋巴瘤
T细胞
发表日期：2023
文献求助 收藏

Correction to: RE‑MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola‑BR), CAR‑T therapies, and lenalidomide/rituximab (R2) based on real‑world data in patients with relapsed/refractory diffuse large B‑cell lymphoma

更正：RE-MIND2：基于真实世界数据，比较 tafasitamab 联合来那度胺与 polatuzumab vedotin/bendamustine/rituximab (pola-BR)、CAR-T 疗法以及来那度胺/rituximab (R2) 在复发/难治性弥漫性大 B 细胞淋巴瘤患者中的疗效

期刊:Annals of Hematology
影响因子:2.4
doi:10.1007/s00277-023-05321-3
Nowakowski, Grzegorz S; Yoon, Dok Hyun; Mondello, Patrizia; Joffe, Erel; Peters, Anthea; Fleury, Isabelle; Greil, Richard; Ku, Matthew; Marks, Reinhard; Kim, Kibum; Zinzani, Pier Luigi; Trotman, Judith; Sabatelli, Lorenzo; Waltl, Eva E; Winderlich, Mark; Sporchia, Andrea; Kurukulasuriya, Nuwan C; Cordoba, Raul; Hess, Georg; Salles, Gilles
细胞生物学
淋巴瘤
T细胞
发表日期：2023
文献求助 收藏

Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study

塔法西他单抗联合来那度胺治疗复发/难治性弥漫性大B细胞淋巴瘤疗效优于全身治疗：RE-MIND2，一项观察性回顾性匹配队列研究

期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-21-3648
Nowakowski, Grzegorz S; Yoon, Dok Hyun; Peters, Anthea; Mondello, Patrizia; Joffe, Erel; Fleury, Isabelle; Greil, Richard; Ku, Matthew; Marks, Reinhard; Kim, Kibum; Zinzani, Pier Luigi; Trotman, Judith; Huang, Dan; Waltl, Eva E; Winderlich, Mark; Kurukulasuriya, Nuwan C; Ambarkhane, Sumeet; Hess, Georg; Salles, Gilles
B细胞
细胞生物学
淋巴瘤
免疫/内分泌
发表日期：2022
文献求助 收藏

Methodological Rigor and Transparency in Clinical Practice Guidelines for Nutrition Care in Critically Ill Adults: A Systematic Review Using the AGREE II and AGREE-REX Tools

危重成人营养护理临床实践指南的方法学严谨性和透明度：一项使用 AGREE II 和 AGREE-REX 工具的系统评价

期刊:Nutrients
影响因子:5
doi:10.3390/nu14132603
Noyahr, John K; Tatucu-Babet, Oana A; Chapple, Lee-Anne S; Barlow, Christopher Jake; Chapman, Marianne J; Deane, Adam M; Fetterplace, Kate; Hodgson, Carol L; Winderlich, Jacinta; Udy, Andrew A; Marshall, Andrea P; Ridley, Emma J
发表日期：2022
文献求助 收藏

RE-MIND: Comparing Tafasitamab + Lenalidomide (L-MIND) with a Real-world Lenalidomide Monotherapy Cohort in Relapsed or Refractory Diffuse Large B-cell Lymphoma

RE-MIND 研究：在复发或难治性弥漫性大B细胞淋巴瘤中比较他法西他单抗联合来那度胺（L-MIND）与真实世界中来那度胺单药治疗队列

期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-21-1471
Zinzani, Pier Luigi; Rodgers, Thomas; Marino, Dario; Frezzato, Maurizio; Barbui, Anna Maria; Castellino, Claudia; Meli, Erika; Fowler, Nathan H; Salles, Gilles; Feinberg, Bruce; Kurukulasuriya, Nuwan C; Tillmanns, Sascha; Parche, Stephan; Dey, Debarshi; Fingerle-Rowson, Günter; Ambarkhane, Sumeet; Winderlich, Mark; Nowakowski, Grzegorz S
B细胞
细胞生物学
淋巴瘤
免疫/内分泌
发表日期：2021
文献求助 收藏

A phase 2a, single-arm, open-label study of tafasitamab, a humanized, Fc-modified, anti-CD19 antibody, in patients with relapsed/refractory B-precursor cell acute lymphoblastic leukemia

一项针对复发/难治性B前体细胞急性淋巴细胞白血病患者的tafasitamab（一种人源化、Fc修饰的抗CD19抗体）的2a期单臂开放标签研究。

期刊:Cancer
影响因子:5.1
doi:10.1002/cncr.33796
Klisovic, Rebecca B; Leung, Wing H; Brugger, Wolfram; Dirnberger-Hertweck, Maren; Winderlich, Mark; Ambarkhane, Sumeet V; Jabbour, Elias J
白血病
细胞生物学
CD19
发表日期：2021
文献求助 收藏